EMA Application withdrawn: Aquilda (satavaptan) — Sanofi-Aventis

View source ↗

Summary

The EMA withdrew the application for Aquilda (satavaptan) by Sanofi-Aventis for the treatment of hyponatremia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyponatremia

Drugs mentioned

• Aquilda (satavaptan)

Snippet

Status: Application withdrawn. Therapeutic area: Hyponatremia. MAH: Sanofi-Aventis. Decision date: 31/12/2009